PYC Therapeutics Limited (ASX:PYC) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Rights offering of new fully paid ordinary shares (retail entitlement offer) Closed: A$47M in the latest tranche · A$1.5 a share · E&P Capital Pty Ltd +2 Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Bloom Burton Securities Inc. (co-lead) Use of proceeds: Advance PYC-003, PYC-002, VP-001 and PYC-001 drug candidates toward registrational or first-in-human trials, plus working capital, R&D and costs | Mar 4, 2026 | |
| Private placement of fully paid ordinary shares Closed: A$128M raised · A$1.5 a share · Bloom Burton Securities Inc. Dealers: Bloom Burton Securities Inc. (lead) Buyers: RA Capital Management; Perceptive Advisors; Driehaus Capital Management; MPM BioImpact; Rock Springs Capital; RTW Investments Use of proceeds: Extend cash runway through CY2030 to deliver human safety and efficacy data for all four drug development programs | Feb 4, 2026 | US$89.6M |
| Rights offering of new fully paid ordinary shares Announced: about A$145.8M · A$1.25 a share · E&P Capital Pty Ltd +6 Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Custom Binders Pty Ltd, John Baird, Sami Zouad, Adrian Bonaddio, Dr Yang Sheng Yeo & Ms Esther Mei Yen Liaw as trustees for the Papy Family Trust Buyers: Alan Tribe (intends to subscribe for New Shares with a value of A$35 million) Insiders: Chairman Alan Tribe, holding 34% of shares, intends to subscribe for New Shares with a value of A$35 million Use of proceeds: Advance blinding eye disease, polycystic kidney disease and Phelan-McDermid Syndrome drug candidates through human trials; working capital and offer costs | Feb 17, 2025 | US$92.69M |